Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy

Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these curable disease stages. Methods: This study (WJOG12319...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Subjects:	Soluble PD-1 Soluble PD-L1 Soluble CTLA-4 Non–small cell lung cancer Adjuvant chemotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364323001339